Mark Hyman, MD describes it: the mother of all antioxidants, the master detoxifier and maestro of the immune system. Levels of glutathione naturally decline with age, chronic illness, poor nutrition, environmental toxin exposure, and chronic stress making targeted replenishment particularly valuable for patients managing complex or long-standing health concerns
Patients who may require Schedule 8 CNS stimulant medication should be referred to a specialist for assessment
Patients should never extend medication use intentionally to save costs
2019:chap 72
Plan your bachelor or bachelorette party in Arizona with IV recovery built in
Insurance Coverage Predictions CagriSema (Advantage: Semaglutide Component): Leverages Wegovy's established coverage "Combination of proven medication + new molecule" easier sell to insurers Predicted coverage: 50-60% of commercial plans initially Retatrutide (Challenge: Novel Molecule): Entirely new drug class, no established coverage Higher efficacy but also higher side effects Will likely require trial-and-failure of cheaper options Predicted coverage: 40-50% of commercial plans initially Clinical Trial Populations and Indications CagriSema: Diabetes Focus REDEFINE-1: Obesity without diabetes (3,417 participants) REDEFINE-2: Obesity WITH type 2 diabetes (1,206 participants) REIMAGINE Program: Additional diabetes-focused trials Advantage: Strong diabetes data positions CagriSema for dual obesity + diabetes indications, like tirzepatide (Mounjaro/Zepbound)
